Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1994 2
1995 1
1996 1
1997 3
1998 4
1999 5
2000 3
2001 3
2002 3
2003 8
2004 11
2005 5
2006 11
2007 12
2008 6
2009 7
2010 10
2011 12
2012 7
2013 11
2014 11
2015 11
2016 18
2017 14
2018 13
2019 15
2020 15
2021 21
2022 17
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

239 results
Results by year
Filters applied: . Clear all
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. Among authors: grohe c. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang Z, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Atasoy A, Herbst RS, Tsuboi M. Wu YL, et al. Among authors: grohe c. J Thorac Oncol. 2022 Mar;17(3):423-433. doi: 10.1016/j.jtho.2021.10.014. Epub 2021 Nov 2. J Thorac Oncol. 2022. PMID: 34740861 Free article. Clinical Trial.
SIADH: differential diagnosis and clinical management.
Peri A, Grohé C, Berardi R, Runkle I. Peri A, et al. Among authors: grohe c. Endocrine. 2017 Jan;55(1):311-319. doi: 10.1007/s12020-016-0936-3. Epub 2016 Mar 30. Endocrine. 2017. PMID: 27025948
[Pneumonia].
Grohé C. Grohé C. Dtsch Med Wochenschr. 2020 Mar;145(6):345. doi: 10.1055/a-0952-9509. Epub 2020 Mar 19. Dtsch Med Wochenschr. 2020. PMID: 32191974 German. No abstract available.
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A; RELIEF investigators. Behr J, et al. Among authors: grohe c. Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30. Lancet Respir Med. 2021. PMID: 33798455 Clinical Trial.
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, Heydt C, Serke M, Fischer R, Schulte W, Gerigk U, Nogova L, Ko YD, Abdulla DSY, Riedel R, Kambartel KO, Lorenz J, Sauerland I, Randerath W, Kaminsky B, Hagmeyer L, Grohé C, Eisert A, Frank R, Gogl L, Schaepers C, Holzem A, Hellmich M, Thomas RK, Peifer M, Sos ML, Büttner R, Wolf J. Scheffler M, et al. Among authors: grohe c. J Thorac Oncol. 2019 Apr;14(4):606-616. doi: 10.1016/j.jtho.2018.12.013. Epub 2018 Dec 31. J Thorac Oncol. 2019. PMID: 30605727 Free article.
[Sarcoidosis].
Pabst S, Skowasch D, Grohé C. Pabst S, et al. Among authors: grohe c. Pneumologie. 2012 Feb;66(2):96-109, quiz 110. doi: 10.1055/s-0030-1257126. Epub 2012 Feb 15. Pneumologie. 2012. PMID: 22337329 Free article. Review. German. No abstract available.
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Majem M, et al. Among authors: grohe c. Clin Cancer Res. 2022 Jun 1;28(11):2286-2296. doi: 10.1158/1078-0432.CCR-21-3530. Clin Cancer Res. 2022. PMID: 35012927 Free PMC article.
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. Wu YL, et al. Among authors: grohe c. Future Oncol. 2021 Dec 1;17(35):4827-4835. doi: 10.2217/fon-2021-0752. Epub 2021 Nov 1. Future Oncol. 2021. PMID: 34723634 Free article.
239 results